Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Company Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $0.99 to $1.05
• 50-Day Range: $0.66 to $1.17
• 52-Week Range: $0.37 to $1.21
• Volume: 1.16 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $230.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.20
• Consensus Rating: Buy

Lineage Cell Therapeutics Stock Analysis - MarketRank™

Lineage Cell Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lineage Cell Therapeutics is -12.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lineage Cell Therapeutics is -12.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lineage Cell Therapeutics has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.30% of the outstanding shares of Lineage Cell Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Lineage Cell Therapeutics has recently increased by 1.26%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lineage Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Lineage Cell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.30% of the outstanding shares of Lineage Cell Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Lineage Cell Therapeutics has recently increased by 1.26%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.12

News Sentiment

Lineage Cell Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.

Search Interest

12 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.80% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LCTX Stock Analysis - Frequently Asked Questions

How have LCTX shares performed this year?

Lineage Cell Therapeutics' stock was trading at $0.5150 at the beginning of 2025. Since then, LCTX shares have increased by 96.1% and is now trading at $1.01.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 169.57% and a negative trailing twelve-month return on equity of 22.64%.
Read the conference call transcript.

Who are Lineage Cell Therapeutics' major shareholders?

Lineage Cell Therapeutics' top institutional shareholders include Defender Capital LLC. (2.97%), Geode Capital Management LLC (1.06%), Y Intercept Hong Kong Ltd (0.18%) and Ground Swell Capital LLC (0.05%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe.
View institutional ownership trends.

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 8/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:LCTX
• CIK: 876343
• Web: www.lineagecell.com
• Phone: (442) 287-8963
• Fax: 510-521-3389
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lineage Cell Therapeutics: $4.20
• High Price Target: $9.00
• Low Price Target: $2.00
• Potential Upside/Downside: +317.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.61 million
• Net Margins: -169.57%
• Pretax Margin: -169.16%
• Return on Equity: -22.64%
• Return on Assets: -15.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.82
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $9.50 million
• Price / Sales: 24.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 228,360,000
• Free Float: 167,157,000
• Market Cap: $229.50 million
• Optionable: Not Optionable
• Beta: 1.66